Last reviewed · How we verify
18F-AV1451
At a glance
| Generic name | 18F-AV1451 |
|---|---|
| Also known as | TAU |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- Longitudinal Early-onset Alzheimer's Disease Study Protocol
- UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy (PHASE1)
- Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
- Tau PET Outcomes With Anti-amyloid Immunotherapies (PHASE2)
- Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (PHASE1)
- Tau PET Imaging in the NACC Study Cohort
- PET Tau - Neurodegenerative Disease Imaging (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-AV1451 CI brief — competitive landscape report
- 18F-AV1451 updates RSS · CI watch RSS
- Mayo Clinic portfolio CI